Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

Annals of the Rheumatic Diseases

Volumn 57, Issue 9, 1998, Pages 545-549

  Perez Ruiz, F ^a   Alonso Ruiz, A ^a   Calabozo, M ^a   Herrero Beites, A ^b   Garcia Erauskin G ^a   Ruiz Lucea, E ^a  

^a HOSPITAL DE CRUCES   (Spain)

^b Hospital de Gorliz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE;

ADULT; AGED; ALCOHOL ABSTINENCE; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GOUT; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; WEIGHT REDUCTION;

EID: 0031662935     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.57.9.545     Document Type: Article

References (50)

1. Cohen H. Gout. In: Copeman WSC, ed. Textbook of the rheumatic diseases. 1st ed. Edinburgh: E and S Livingstone, 1948:249-305.
2. Yu TF. Milestones in the treatment of gout. Am J Med 1974;56:676-85.
3. Palella TD, Kelley WN. An approach to hyperuricemia and gout. Geriatrics 1984;39:89-102.
4. Wortmann RL. Management of hyperuricemia. In: McCarthy DJ, ed. Arthritis and allied conditions. 11th ed. Philadelphia: Lee and Febiger, 1989:1677-90.
5. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am 1988;14:441-57.
6. Diamond HS. Control of crystal-induced arthropathies. Rheum Dis Clin North Am 1989;15:557-67.
7. Fam AG. Strategies and controversies in the treatment of gout and hyperuricemia. Baillieres Clin Rheumatol 1990;4: 177-83.
8. Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol 1995;22:1621-3.
9. Simkin PA. Management of gout. Ann Intern Med 1979;90:812-16.
10. Ferraz MB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol 1995;22: 1618-20.
11. Ferraz MB, O'Brien B. A cost effective analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995;22:908-14.
12. Rosenthal AK, Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am 1995;21: 151-61.
13. Fiddis RW, Vlachos N, Calvert PD. Studies on crystallisation in relation to gout. Ann Rheum Dis 1983;42 (suppl): 12-15.
14. Gast LF. Reduce serum uric acid levels before withdrawing antihyperuricemic therapy in patients with tophaceous gout. [Letter]. Arthritis Rheum 1992;35:1252.
15. Mc Carthy GM, Wortmann RL. [Reply to the letter to the editor]. Arthritis Rheum 1992;35:1252.
16. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
17. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, YU TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20: 895-900.
18. Ralston SH, Capell HA, Sturrock RD. Alcoholic response to treatment of gout. BMJ 1988;296:1641-2.
19. Nichols A, Scott JT. Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 1972;ii:1223-4.
20. Garcia J, Mateos F, Jimenez M, Ramos T. Renal excretion of hypoxanthine and xanthine in primary gout. Am J Med 1988;85:533-7.
21. Kaehny WD, Tangel DJ, Johnson AM, Kimberling WJ, Schrier RW, Gabow PA. Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. Am J Med 1990;89:49-52.
22. Dean AG, Dean JA, Coulumbier D, Burton KA, Brendel KA, Smith DC, et al. Epi Info, version 6: a word processing, database, and statistics program for epidemiology on microcomputers. Atlanta, Georgia: Centers for Disease Control and Prevention, 1994.
23. McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991; 34:1489-94.
24. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989;16:1246-8.
25. Loebl WY, Scott JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974;33:304-7.
26. Nakayama DA, Barthelemy C, Carrera G, Lightfoot RW Jr, Wortmann RL. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984;27:468-71
27. Lieshout-Zuidema MF, Breedveld F. Withdrawal of long-term antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993;20:1383-5.
28. Gast LF. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol 1987;1:70-3.
29. Boss GR, Seegmiller JE. Hyperuricemia and gout. N Engl J Med 1979;300:1459-68.
30. Wolf F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol 1991;18:1232-4.
31. Bellamy K, Gilbert JR, Brooks PM, Emmerson BT, Campbell J. A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol 1988;15: 1841-7.
32. Harris CM, Lloyd DCEF, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995;48: 1153-8.
33. Levinson DJ. Clinical gout and the pathogenesis of hyperuricemia. In: McCarty DJ, ed. Arthritis and allied conditions. 11th ed. Philadelphia: Lee and Febiger, 1989:1645-76.
34. Cohen MG, Emmerson BT. Crystal arthropathies: gout. In: Kippel JH, Dieppe PA, eds. Rheumatology. 1st ed. London: Mosby-Years Book Europe, 1994:7-12.1 7-12.16.
35. Perez-Ruiz F, Calabozo M, Alonso-Ruiz A, Ruiz-Lucea E, Herrero-Beites A. Analysis of the methods for the classification of renal handling of urate in gout. Arthritis Rheum 1997;40 (suppl):S48.
36. Cutrin C, Nieto E, Batalla A, Casal L, Perez E, Lorenzo V. Toxic hepatitis due to cincophen. Report of three cases. [English abstract]. Med Clin (Barc) 1991;97:104-6.
37. Sinclair DS, Fox IH. The pharmacology of hypouricemic effect of benzbromarone. J Rheumatol 1974;2:437-45.
38. Sorensen LB, Levinson DJ. Clinical evaluation of benzbromarone. A new uricosuric drug. Arthritis Rheum 1976;19: 183-90.
39. Masbernard A, Giudicelli CP. Ten years' experience with benzbromarone in the management of gout. South Afr Med J 1981;59:701-6.
40. Zürcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients patients: a prospective study. Nephrol Dial Transplant 1994;9:548-51.
41. Asplin JR. Uric acid stones. Semin Nephrol 1996;5:412-24.
42. Bautler AM, Rull M, Schlechinger N, Baker DG, Hoffman BI, Schumacher HR Jr. Allopurinol may have protective effect against acute gouty arthritis independent from its hypouricemic action. Arthritis Rheum 1996;39 suppl:S86.
43. WHO collaboratory center for drug statistics methodology. Anatomical therapeutic chemical (ATC) classification index. Including defined daily dosis (DDDs) for plain substances. Oslo: WHO, 1993.
44. Singer TZ, Wallace S. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7.
45. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: Description and guidelines for prescription in patients with renal insufficiency. Am J Med 1984;76:47-56.
46. Cummings D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996; 61:1661-2.
47. Walter-Sack I, de Vries JX, von Bubnoff A, Pfleilschifler V, Reedsch R. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites? Eur J Med Res 1995;1:16-20.
48. Van der Klauw MM, Houtman PM, Stricker BH, Spoelstee P. Hepatic injury caused by benzbromarone. J Hepatol 1994;20:376-9.
49. Gehenot M, Horsmans Y, Rahier J, Geubel AP. Subfulminant hepatitis requiring liver transplantation after benzarone administration. J Hepatol 1994;20:842-6.
50. Hautekeete ML, Henrion J, Naegels S, De Neve A, Adler M, Deprez C, et al. Severe hepatotoxicity related to benzarone: report of three cases with two fatalities. Liver 1995;15:25-9.